A detailed history of Itau Unibanco Holding S.A. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Itau Unibanco Holding S.A. holds 100 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$0
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$38.96 - $42.75 $3,896 - $4,275
100 New
100 $4,000
Q4 2023

Feb 14, 2024

SELL
$20.27 - $42.44 $121 - $254
-6 Reduced 6.12%
92 $3,000
Q2 2023

Aug 14, 2023

SELL
$23.9 - $35.38 $478 - $707
-20 Reduced 16.95%
98 $3,000
Q4 2022

Feb 09, 2023

SELL
$25.35 - $31.96 $76 - $95
-3 Reduced 2.48%
118 $3,000
Q2 2022

Aug 15, 2022

BUY
$20.62 - $37.15 $2,495 - $4,495
121 New
121 $3,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Itau Unibanco Holding S.A. Portfolio

Follow Itau Unibanco Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Itau Unibanco Holding S.A. with notifications on news.